Kingston, Ontario maker of Amplifi ID, a portable analyzer that pairs Raman spectroscopy with nanofabricated surface-enhanced Raman scattering (SERS) cartridges to identify chemical compounds in samples at the point of need.
Canadian innovation builds a brighter tomorrow.
Spectra Plasmonics states that "From government agencies combatting the overdose crisis, to clean technology companies developing a more sustainable future, our products allow organizations to detect the chemicals they need, when and where they need to. With actionable chemical insights, Spectra's technology helps to drive innovation and safeguard our world." It describes itself as "a Canadian owned and operated organization that was founded as a spinoff company from Queen's University in Kingston, Ontario", adding that "Today our technology team is led by graduates of some of the top Master's and PhD programs in the country, and our collective expertise is what drives our ability to develop high quality, easy to use products that deliver chemical analysis + insight to the industries that need it the most."
Received $191,984 from FedDev Ontario in March 2025 to adopt automation technologies as it scales nanofabrication of its diagnostic chip. canada.ca
Awarded $150,000 in total project funding under the Ontario Genomics BioCreate Program to build bacteria-sensing tests for food producers. ontariogenomics.ca
Amplifi ID is one of four technologies evaluated in Toronto's Drug Checking Service performance assessment, alongside instruments from Bruker, Scatr and Waters. drugchecking.community
Received its first US patent in February 2022, and three Ontario community health centres adopted the technology for safe-injection sites that year. queensu.ca
Incorporated in 2017 as a technology spin-off from Queen's University, per a Government of Canada announcement. canada.ca
Products Spectra Plasmonics publishes on its own site. Each card links to the page it was taken from.
Portable chemical analyzer
A portable drug analysis and intelligence system, offered in Public Health configurations for harm reduction and syringe services and Public Safety configurations for border services, law enforcement and coroners' offices.
Learn moreAnalysis mode
Analyzes samples directly through packaging, with no sample handling required.
Learn moreConsumable SERS substrate
Consumable cartridges enabling micro-sample analysis at trace levels, compared against a database of molecular fingerprints.
Learn moreGovernment support actually received. Unpublished amounts are left out.
FedDev Ontario support to adopt automation technologies and scale nanofabrication of its diagnostic chip
Ontario Genomics BioCreate Program, funded by FedDev Ontario and Ontario Genomics, for bacteria-sensing tests for food producers
Toronto's Drug Checking Service published a comparative performance assessment of four drug-checking technologies, including Spectra Plasmonics' Amplifi ID, and credits feedback from the company.
FedDev Ontario announced a combined total for seven firms, of which Spectra Plasmonics received $191,984 to adopt automation technologies as it scales nanofabrication of its diagnostic chip.
A company post interviewing a Canadian drug-checking customer following Amplifi ID training and deployment.
Spectra Plasmonics announced the addition of BTMPS to the Amplifi ID detection library.
Sourced from the company's own pages or announcements.
Malcolm Eade
Co-Founder & Chief Executive Officer
Tyler Whitney
Co-Founder & Chief Financial Officer
Juan Gomez
Chief Technology Officer
Terms the company uses about its own work.
Other companies in Semiconductors & Photonics.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.
